Acquisition of Neogene Therapeutics completed
AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
Acquisition provides access to next-generation T-cell receptor therapies with promising potential for targeting solid tumors SANTA MONICA, Calif., and AMSTERDAM, November 28, 2022 – Neogene Therapeutics, Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), today announced it has entered into a definitive agreement to […]
Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors
Approval Marks Neogene’s Transition to a Clinical-Stage Company NT-125 is a unique, multi-specific TCR therapy targeting neoantigens specific to each individual cancer patient SANTA MONICA, Calif., and AMSTERDAM, May 10, 2022 – Neogene Therapeutics, Inc., a global biotechnology company focused on discovering, developing, and manufacturing novel, transformative TCR therapies targeting neoantigens in solid cancers, today […]
Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer
Portfolio of TCRs developed in the laboratory of immunotherapy pioneer Steven Rosenberg, M.D., Ph.D. at the National Cancer Institute, combined with Neogene’s proprietary TCR isolation platform, provides expanded opportunities to target multiple neoantigens in individual patients Neogene plans to evaluate both autologous and allogeneic T cell therapies targeting neoantigens in a broad spectrum of solid […]
Neogene Therapeutics Appoints Raphaël Rousseau, M.D., Ph.D., as Chief Medical Officer
Dr. Rousseau brings extensive scientific expertise and industry experience in the development of T cell therapies and will lead Neogene’s efforts to advance next-generation, fully individualized T cell therapies into the clinic SANTA MONICA, Calif., and AMSTERDAM, December 16, 2021 – Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully […]
Neogene Therapeutics Appoints Han Lee, Ph.D., MBA, as Chief Financial Officer
Dr. Lee will support Neogene’s continued growth as it advances a new class of fully individualized TCR therapies for solid tumors to the clinic SANTA MONICA, Calif., and AMSTERDAM, September 14, 2021 – Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully individualized T cell receptor (TCR) therapies to treat […]
Neogene Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA as Chief Operating Officer
Most recently served as senior vice president, U.S. Oncology, at Bristol Myers Squibb and brings an industry-leading track record in oncology and general management Will lead expansion of Neogene with U.S. headquarters in Santa Monica, Calif., as the company’s location for its cell therapy development group spear-heading the clinical translation of novel neo-antigen T cell […]
Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine
Renowned immunologist and T cell engineering expert awarded distinguished prize for conducting fundamental translational research of substantial significance for medicine NEW YORK and AMSTERDAM, January 26, 2021 – Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company’s […]
Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies
Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies SOUTH SAN FRANCISCO, Calif. and AMSTERDAM, The Netherlands – October 13, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and […]
Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors
Four Additional Board Members Appointed to Complement Founding Expertise NEW YORK and AMSTERDAM, October 6, 2020 – Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of Franz B. Humer, Ph.D., as Executive Chairman of the Board of […]
